Taylor Morrison Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Taylor Morrison Home Corporation

KSF and former Louisiana AG Charles C. Foti are investigating the proposed sale of Taylor Morrison Home (NYSE: TMHC) to Berkshire Hathaway (NYSE: BRK.A/BRK.B). The deal would pay TMHC shareholders $72.50 per share in cash, and the firm says it is assessing whether the transaction terms/considerations are fair. The investigation introduces some uncertainty around deal completion and shareholder value.

Analysis

This is a classic special-situation setup where the only real variable is deal certainty, not fundamental homebuilding value. A plaintiff-style review typically matters only if it uncovers process defects, side payments, or a revised bidder landscape; absent that, it mostly adds a few basis points of spread and some time-value drag. Berkshire’s balance sheet removes financing risk, so TMHC should trade more like a low-volatility merger arb than a housing beta name until closing risk is repriced.

The more interesting second-order effect is not on Berkshire, which can absorb this without moving the needle, but on the arb community: if the spread widens on legal noise, it becomes a carry trade rather than a directional one. That means the best risk/reward is usually in timing the entry after headline-driven dislocations, not front-running the initial announcement. A break would likely require something material and verifiable — a superior bid, regulatory issue, or evidence the process was flawed — not just routine litigation chatter.

Contrarian view: the market often overestimates the importance of these investigations in cash deals backed by a highly rated acquirer. If TMHC already trades near deal value, the upside from owning it here is mostly the remaining spread, while the downside if the deal breaks is meaningful but event-specific. The key near-term catalyst is whether the spread tightens or stays sticky over the next 1-3 weeks; over 6-18 months, this is likely just a footnote unless the transaction collapses and reintroduces housing-cycle exposure.

Key Decisions for Investors

• Watch TMHC as a merger-arb instrument rather than a homebuilder beta proxy; only initiate long exposure if the spread widens meaningfully versus implied close probability and the market is offering attractive annualized carry over the expected closing window.
• If already long TMHC, hedge event risk with a small short in XHB or LEN/DHI only if the basket is rallying on housing-beta sympathy; otherwise keep the position self-contained because this deal is idiosyncratic, not sector-defining.
• Avoid adding to BRK.B on this headline alone; the acquisition is too small relative to Berkshire’s capital base to justify a trade unless the stock weakness creates a separate valuation dislocation.
• Set a falsifier alert on TMHC: if the stock trades materially below implied deal value without a corresponding new legal filing, regulatory issue, or bidder event, the market is likely overpricing noise and the spread should normalize.
• If you want optionality, prefer a limited-risk TMHC call-spread only after the legal overhang causes a temporary spread blowout; the best payoff is on mean reversion into close, not on chasing the initial headline.